全球抗病毒藥劑市場分析預測：2008-2023年

全球抗病毒藥劑市場分析預測：2008-2023年 是由出版商Visiongain在2008年09月所出版的。 這份英文市場調查報告書包含145 pages 價格從美金2331起跳。

簡介

目錄

Abstract

Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market. Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market. Its double-digit growth makes it a standout segment within the general anti-infective therapeutic class. You should be maximizing your opportunities in this market. The opportunities for success are there now, you should capitalize on them immediately.

The key driver of the market is the rapid development of resistance to existing therapies by the evolving viruses. The constant need to update the pipeline fuels your investigative and commercial interest in this market - so you must act on this today. This report - Global Antivirals Market, 2008-2023 - analyses the global antiviral market comprehensively, outlining where you should aim your future developments to guarantee success. The analyses tackle different aspects of the market, including the leading therapeutic classes, leading antiviral products, key industrial players as partners and financial prospects and opportunities. The report also delivers in-depth predictions concerning how the market will develop from present until 2023.

Global Antivirals Market, 2008-2023 examines the market for antivirals critically, through comprehensive primary and secondary research. In addition to consultation with experts in the industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Essentially, visiongain also applied unique in-house techniques such as our developed financial forecasting, SWOT analyses and qualitative projections which are unavailable elsewhere. The result is a comprehensive market-focused study with detailed financial analyses and uniquely informed opinion on the future of the antivirals market.

In particular, our new Global Antivirals Market 2008-2023 report concentrates on the following essential aspects of that market:

• Antiviral drugs assessment and opportunities
• Key industrial players in the global antivirals market
• Forecasts of global antivirals market from 2008-2023, including in-house developed forecasts of the leading therapeutic agents
• Forecasts for the antiviral therapies in the seven leading developed pharmaceutical country markets and two leading developing markets
• Drivers and opportunities in the global antivirals market
• Restraints and threats in the global antivirals market
• Key opinion from relevant experts - full interview transcripts are included with the report (unavailable anywhere else)
• Coverage of pipeline developments in the antivirals market, with discussion of trends from the present onwards

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the antivirals industry from 2008-2023, including sales forecasts, major growth areas and most exciting pipeline developments
• To discover predicted revenues, growth rates and other key metrics in the global antivirals market from 2008-2023, with leading brands and principal market segments covered
• To determine the forces that influence the global antivirals market:
• Drivers and restraints on that market
• Competition
• Strengths, weaknesses, opportunities and threats.
• To find out where the global antivirals market is heading from 2008 onwards - both technologically and commercially

The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

Table of Contents

1 Executive Summary

• 1.1 Aims of This Report
• 1.2 A Brief Overview of the Chapters

2 Introduction

• 2.1 What is a Virus?
• 2.2 History of Virology
  • 2.2.1 Origin of Viruses
  • 2.2.2 Historical Developments in Virology
• 2.3 Classification of Viruses
  • 2.3.1 DNA Viruses
  • 2.3.2 RNA Viruses
  • 2.3.3 Reverse Transcribing Viruses
• 2.4 Introduction to Viral Infections
  • 2.4.1 Viral Life Cycle
  • 2.4.2 Intrinsic Human Defences against Virus
• 2.5 How Do Antivirals Work?
  • 2.5.1 Approach to Life Cycle Management
  • 2.5.1.1 Before Cell Entry
  • 2.5.1.2 During Viral Synthesis
  • 2.5.1.3 Release Phase
  • 2.5.2 Immune System Modulating
• 2.6 Antivirals Battle Highly Mutational Viral Genomes
• 2.7 The World Anti-Infective Market
  • 2.7.1 Market Shares

3 The Global Market for Anti-Viral Drugs, 2008-2023

• 3.1 The Global Anti-Viral Market Generated High Revenues in 2007
  • 3.1.1 Leading Segments in the Global Anti-Viral Market
  • 3.1.2 Reverse Transcriptase Inhibitors, Immunoglobulin, Protease Inhibitors and Vaccine Segments
• 3.2 Global Anti-Viral Market Forecast, 2008-2023
• 3.3 Global Anti-Viral Market by Disease Area, 2008-2023
• 3.4 The Rise of the Hepatitis Segment from 2008 to 2013
• 3.5 The HIV Market Impeded by Patent Issues
  • 3.5.1 Anti-HIV Agents Facing Looming Patent Expiries
  • 3.5.2 Controversy Surrounding Patent Rights
• 3.6 The Influenza Segment Growth is Hampered by Conflicts
• 3.7 The Global Anti-Viral Market Will Undergo Shift
• 3.8 Leading Anti-Viral Brands and Forecast, 2008-2023
  • 3.8.1 Will Tamiflu Retain its Leadership Position?
  • 3.8.2 Combination Therapy Deemed Most Effective
  • 3.8.3 Pegasys-Ribavirin Combination Therapy
  • 3.8.4 Atripla - the Way Forward?
• 3.9 The Anti-Viral Market and Investment Activities

4 Factors Affecting the World Anti-Viral Market, 2008-2023

• 4.1 SWOT Analysis of the Anti-Viral Market
• 4.2 There is Much Reason for Optimism in the Anti-Viral Market
  • 4.2.1 Drug Resistance is a Major Concern, but Stimulates Research Activity
  • 4.2.2 Chronic Indications Ensure Long-Term Demand for Antivirals
  • 4.2.3 Outbreaks of Viral Infections Give Rise to Major Global Public Health Crises
  • 4.2.4 Low Diagnostic Rate Means that the Majority of Patients Are Unaware of Their Infections
• 4.3 Current Antiviral Treatments Marred by High Toxicity and Low Patient Compliance
• 4.4 The Threat of Bio-generic Penetration
  • 4.4.1 Looming Patent Expiry Threatens Some Leading Brands
  • 4.4.2 Does the Pipeline Have Enough Potential to Replace the Aging Brands?
• 4.5 Variability of Novel Targets and Mechanisms
• 4.6 Investment and Commercial Obstacles
  • 4.6.1 Low Prevalence of Treatable Viral Diseases
  • 4.6.2 Low Profitability from the Developing Countries
• 4.7 The Market Needs to Overcome Economic and Political Obstacles to Gain Access to Patients in Need
  • 4.7.1 Will the Expanding Patient Population Drive Market Growth? A Case Study of the HIV Market
  • 4.7.2 Expensiveness of Antiviral Treatments Forces Market Exclusivity and Limits Market Growth
  • 4.7.3 Conjoint Effort from the Public and Private Domains to Achieve Greater Accessibility is a Positive Step Forward
• 4.8 How Will the Manufacturers Answer to Public Demands for Enhancing Treatment Availability?
  • 4.8.1 Production Rate Unable to Meet Demands
  • 4.8.2 The Controversy Towards Overriding Patent Rights
• 4.9 Are Vaccines Friends or Foes to the Antiviral Market?

5 Leading Companies in the Antiviral Market, 2008-2023

• 5.1 GSK, Roche, Merck, Gilead Sciences and Bristol-Myers Squibb
• 5.2 Is GSK' s Market Dominance in Jeopardy?
• 5.3 Roche' s Pipeline
• 5.4 What is Merck' s Competitive Edge in the Antiviral Market?
• 5.5 Gilead Sciences and Bristol-Myers Squibb Carve into the HIV Market

6 Leading Antiviral Brands, Forecasts and Analyses, 2008-2023

• 6.1 Top 15 Marketed Antivirals of 2007
• 6.2 Tamiflu
• 6.3 Gardasil
• 6.4 Valtrex
• 6.5 Pegasys
• 6.6 Truvada
• 6.7 Varivax
• 6.8 Synagis
• 6.9 Reyataz
• 6.10 Kaletra
• 6.11 Sustiva
• 6.12 Atripla
• 6.13 Combivir
• 6.14 Peg-Intron
• 6.15 Epzicom
• 6.16 Viread

7 Antivirals in the Leading Pharmaceutical Markets, Forecasts and Analysis, 2008-2023

• 7.1 Sales of Antivirals in the Leading Pharmaceutical Markets in 2007
• 7.2 Market Performance of Antivirals in the Leading Pharmaceutical Nations, 2008-2023
• 7.3 Will the US Retain Dominance?
• 7.4 Other Industrialised Countries to Undergo Steady Growth
• 7.5 How Will the Leading Developing Countries Fare in the Global Antivirals Market?

8 Promising Anti-Viral Technologies and Pipeline Developments

• 8.1 HIV Pipeline Development
  • 8.1.1 Research Direction
  • 8.1.2 Viral Enzymes as Targets
  • 8.1.3 NNRTI
  • 8.1.3.1 Intelence
  • 8.1.3.2 Rilpivirine
  • 8.1.4 NRTI
  • 8.1.4.1 Apricitabine
  • 8.1.5 Host Proteins as Targets
  • 8.1.6 Viral-Entry Inhibitors: Attachment, Entry and Fusion Inhibitors
  • 8.1.6.1 Selzentry/Celsentri
  • 8.1.6.2 Vicriviroc
  • 8.1.7 Integrase Inhibitors
  • 8.1.7.1 Isentress
  • 8.1.7.2 Elvitegravir
  • 8.1.8 Maturation Inhibitors
  • 8.1.8.1 Bevirimat
• 8.2 Hepatitis Pipeline Development
  • 8.2.1 Research Direction
  • 8.2.2 Interferons
  • 8.2.2.1 Albuferon
  • 8.2.3 NS3 Protease Inhibitors
  • 8.2.3.1 Telaprevir
  • 8.2.3.2 Boceprevir
  • 8.2.4 Polymerase Inhibitors
  • 8.2.4.1 R7128
• 8.3 Novel Technologies Head the Next Wave of Anti-Viral Drug Exploration
  • 8.3.1 Could Monoclonal Antibodies Surpass the Dominant Small-Molecules?
  • 8.3.2 RNA Interference Technology Raises Investment Interest

9 Interviews with Relevant Experts - Discussion of Current and Future Trends

• 9.1 Interview 1: Professor Erik De Clercq, Emeritus Professor, Rega Institute for Medical Research, K.U. Leuven, Belgium.
  • 9.1.1 Promising Sub-Markets
  • 9.1.2 Market Drivers and Restraints
  • 9.1.3 Promising R&D Programmes
  • 9.1.4 Market Direction
• 9.2 Interview 2: Dr. Michael Kinch, VP, Research and Development, Functional Genetics, Maryland, USA
  • 9.2.1 Promising Sub-Markets
  • 9.2.2 Market Drivers and Restraints
  • 9.2.3 Arguments for Host-Oriented Therapeutic Approach
  • 9.2.4 Biologicals Versus Small Molecules

10 Conclusions

• 10.1 Excitement Surrounds the Antivirals Market
• 10.2 The Next Market Leader
• 10.3 Hepatitis Segment Drives Innovative Antiviral Research
• 10.4 Pipeline Development
• 10.5 The Future of Antivirals

List of Tables

• Table 2.1, Historical Developments in Virology
• Table 2.2, Categorisation of Clinically Significant Viruses
• Table 2.3, The World Anti-Infective Market, Sales ($bn), 12 months to Q1 2008
• Table 3.1, Antiviral Therapies Blockbusters, Sales ($m) and Market Share (%), 2007
• Table 3.2, Global Anti-Viral Market, Sales ($bn) and Growth (%), 2006-2013, 2018, 2023
• Table 3.3, Global Antiviral Market Breakdown by Disease Area, 2006 and 2007
• Table 3.4, Global Anti-Viral Market by Disease Area, Sales ($bn) and Annual Growth (%), 2006-2013
• Table 3.5, Market Performance of the Hepatitis Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
• Table 3.6, Marketed Antiviral Therapies for HIV/AIDS, Sales ($m), 2007
• Table 3.7, Market Performance of the HIV Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
• Table 3.8, Market Performance of the Influenza Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
• Table 3.9, Global Anti-Viral Market by Disease Area, CAGR (%) and Market Share (%), 2007, 2013, 2018 and 2023
• Table 3.10, Top 15 Anti-Viral Brands, Sales ($m) and Growth (%), 2007
• Table 3.11, Top 15 Anti-Viral Brands, Sales ($m) and Growth (%), 2006-2013
• Table 4.1, SWOT Analysis of the Antiviral Market, 2008
• Table 4.2, Antivirals with Recent or Imminent Patent Expiration
• Table 4.3, Antiviral Patents Approved in the United States
• Table 5.1, Leading Companies in the Antiviral Market, Sales ($bn), 2007
• Table 6.1, Sales of Tamiflu ($m), 2006-2013
• Table 6.2, Sales of Gardasil ($m), 2006-2013
• Table 6.3, Sales of Valtrex ($m), 2006-2013
• Table 6.4, Sales of Pegasys ($m), 2006-2013
• Table 6.5, Sales of Truvada ($m), 2006-2013
• Table 6.6, Sales of Varivax ($m), 2006-2013
• Table 6.7, Sales of Synagis ($m), 2006-2013
• Table 6.8, Sales of Reyataz ($m), 2006-2013
• Table 6.9, Sales of Kaletra ($m), 2006-2013
• Table 6.10, Sales of Sustiva ($m), 2006-2013
• Table 6.11, Sales of Atripla ($m), 2006-2013
• Table 6.12, Sales of Combivir ($m), 2006-2013
• Table 6.13, Sales of Peg-Intron ($m), 2006-2013
• Table 6.14, Sales of Epzicom ($m), 2006-2013
• Table 6.15, Sales of Viread ($m), 2006-2013
• Table 7.1, Antivirals in the Leading Pharmaceutical Markets, Sales ($), Market Share (%) and Annual Growth (%), 2007
• Table 7.2, Antivirals in the Leading Pharmaceutical Markets, Sales ($m), 2007-2013, 2018, 2023
• Table 7.3, Antivirals in the Leading Pharmaceutical Markets, Market Share (%) and CAGR (%), 2007 and 2013
• Table 8.1, HIV Life Cycle and Potential Targets for Antiretrovirals
• Table 8.2, Selected Viral Enzymes Inhibitors in Late Clinical Development
• Table 8.3, Selected Entry Inhibitors in Late Clinical Development
• Table 8.4, Selected Integrase Inhibitors in Late Clinical Development
• Table 8.5, Selected Interferons in Late Stage Development
• Table 8.6, Selected NS3 Protease Inhibitors in Late Clinical Development
• Table 8.7, Selected Polymerase Inhibitors in Late Clinical Development
• Table 8.8, Commercial Development of Antiviral mAbs
• Table 10.1, Global Anti-Viral Market, Sales ($bn) and Growth (%), 2006-2013, 2018, 2023
• Table 10.2, Antiviral Therapies Blockbusters, Sales ($m) and Market Share (%), 2007

List of Figures

• Figure 2.1, Basic Structures of the Influenza Virus
• Figure 2.2, Life Cycle of a Typical RNA Virus
• Figure 2.3, The World Anti-Infective Market, Sales ($bn), 12 months to Q1 2008
• Figure 2.4, The World Anti-Infective Market, Market Share (%), 12 months to Q1 2008
• Figure 3.1, Leading Disease Areas in the Anti-Viral Market, Sales ($bn), 2007
• Figure 3.2, Leading Drug Classes in the Anti-Viral Market, Sales 2007 ($bn)
• Figure 3.3, Global Anti-Viral Market Sales ($m), 2006-2013
• Figure 3.4, Global Antiviral Market by Disease Area, Market Share (%), 2007
• Figure 3.5, Global Anti-Viral Market by Disease Area, Sales ($m), 2006-2013
• Figure 3.6, Global Hepatitis Market, Sales ($bn), 2006-2023
• Figure 3.7, Global HIV Market, Sales ($bn), 2006-2023
• Figure 3.8, Global Influenza Market, Sales ($bn), 2006-2023
• Figure 3.9, Global Antiviral Market by Disease Area, Market Share (%), 2013
• Figure 3.10, Market Share of the Leading Anti-Viral Drugs (%), 2007
• Figure 5.1, Leading Companies in the Antiviral Market, Market Share (%), 2007
• Figure 6.1, Top 15 Marketed Antiviral Therapies, Sales ($m), 2007
• Figure 6.2, Top 15 Marketed Antiviral Therapies, Annual Growth (%), 2007
• Figure 6.3, Sales of Tamiflu ($m), 2006-2023
• Figure 6.4, Sales of Gardasil ($m), 2006-2023
• Figure 6.5, Sales of Valtrex ($m), 2006-2023
• Figure 6.6, Sales of Pegasys ($m), 2006-2023
• Figure 6.7, Sales of Truvada ($m), 2006-2023
• Figure 6.8, Sales of Varivax ($m), 2006-2023
• Figure 6.9, Sales of Synagis ($m), 2006-2023
• Figure 6.10, Sales of Reyataz ($m), 2006-2023
• Figure 6.11, Sales of Kaletra ($m), 2006-2023
• Figure 6.12, Sales of Sustiva ($m), 2006-2023
• Figure 6.13, Sales of Atripla ($m), 2006-2023
• Figure 6.14, Sales of Combivir ($m), 2006-2023
• Figure 6.15, Sales of Peg-Intron ($m), 2006-2023
• Figure 6.16, Sales of Epzicom ($m), 2006-2023
• Figure 6.17, Sales of Viread ($m), 2006-2023
• Figure 7.1, Antivirals in the Leading Pharmaceutical Markets, Sales ($m), 2007
• Figure 7.2, Antivirals in the Leading Pharmaceutical Markets, Market Share (%), 2007
• Figure 7.3, Antivirals in the US Market, Sales ($m), 2008-2013
• Figure 7.4, Antivirals in Other Leading Industrialised Countries, Sales ($m), 2008-2013
• Figure 7.5, Antivirals in China and India, Sales ($m), 2008-2013

Companies listed:

• Abbott
• AIDS Drug Assistance Programme
• Alnylam Pharmaceutical
• AnorMed
• AstraZeneca
• Aurobindo
• Avexa
• Benitec
• Bill and Melinda gates Foundation
• Biolex Therapeutics
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Cipla
• Genentech
• Genzyme
• Gilead Sciences
• Glaxo Wellcome
• GlaxoSmithKline (GSK)
• Hoffmann-La Roche
• Human Genome Sciences
• Incyte
• Intarcia
• International AIDS Vaccine Initiative (NIAID)
• Japan Tobacco
• Johnson and Johnson
• Jointed United Nations Programme on HIV/AIDS (UNAIDS)
• MedImmune
• Medivir
• Merck
• Mitsubishi
• Monogram Biosciences
• Novartis
• OctoPlus
• Panacos
• Pfizer
• Pharmaplaz
• Pharmasset Inc
• Progenics
• Rega Institute for Medical Research
• Samaritan
• Schering-Plough
• Tacere Therapeutics
• Teijin Pharma
• Tibotec
• Tibotec-Virco
• Trimeris
• US Centers for Disease Control and Prevention (CDC)
• US President' s Emergency Plan for AIDS Relief (PEPFAR)
• Vertex Pharmaceuticals
• ViroChem Pharma
• World Bank
• World Health Organization (WHO)

相關商品

抗體和免疫相關市場調查報告書

大腸癌、血管增生、抗體分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

Visiongain發行的生物科技相關市場調查報告書

下一代抗體治療：開發產品線及市場 2011-2021

Next-Generation Antibody Therapies: Pipeline and Market 2011-2021

價格 : US $ 2642

出版日期 : 2011年11月

全球小分子癌症標靶治療市場：2011-2021

Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

價格 : US $ 2642

出版日期 : 2011年11月

表觀遺傳治療及技術:全球市場預測(2011-2021年)

Epigenetic Therapies and Technologies: World Market Prospects 2011-2021

價格 : US $ 2642

出版日期 : 2011年10月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!